Design of iron chelators with therapeutic application
The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Abstract
Iron is essential for the proper functioning of all living cells, however it is toxic when present in excess. Thus, using iron chelators as therapeutic agents, namely chelation therapy, has received increasing attention. The objective of this review is to discuss the factors which should be considered when designing clinically useful iron chelators, to present the application of iron chelators in the treatment of iron overload associated with β-thalassaemia major and sickle cell anaemia, and to highlight the potential applications in the treatment of neurodegenerative disorders and microbial infection. This article reviews recent knowledge centred on these themes and indicates the growing importance of the concept of iron chelation in medicine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An effective iron chelator must be nontoxic, must have higher affinity for ferric iron than bacterial siderophores and must not be recognized by microbial siderophore transporters94.”
From Iron homeostasis in host defence and inflammation (2015) · cites this paper as [94]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Chemistry and biology of siderophores
Hider, R. C., & Kong, X. (2010) · Natural Product Reports · doi:10.1039/b906679a · Cited by 1,722
Self-citationRae, T. D., Schmidt, P. J., Pufahl, R. A., Culotta, V. C., & V. O'Halloran, T. (1999) · Science · doi:10.1126/science.284.5415.805 · Cited by 1,629
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
The metallobiology of Alzheimer's disease
Bush, A. I. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00067-5 · Cited by 1,315
Weinberg, E. D. (1978) · Microbiological Reviews · doi:10.1128/mmbr.42.1.45-66.1978 · Cited by 1,254
Protective effects of the sickle cell gene against malaria morbidity and mortality
Aidoo, M., Terlouw, D. J., Kolczak, M. S., McElroy, P. D., ter Kuile, F. O., Kariuki, S., Nahlen, B. L., Lal, A. A., & Udhayakumar, V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08273-9 · Cited by 700
Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620
Pardridge, W. M., Boado, R. J., & Farrell, C. R. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)38267-x · Cited by 606
Rational Design of Sequestering Agents for Plutonium and Other Actinides
Gorden, A. E. V., Xu, J., Raymond, K. N., & Durbin, P. (2003) · Chemical Reviews · doi:10.1021/cr990114x · Cited by 552
Research works printed but not linked: 11
- Pearson, 1963, J. Am. Chem. Soc., 85, 3535
- Thieken, 1992, FEMS Microbiol. Lett., 94, 37, 10.1111/j.1574-6968.1992.tb05285.x · doi:10.1111/j.1574-6968.1992.tb05285.x · Paper page
- Holander, 1988, Can. J. Gastroenterol., 2, 35A
- Hider, 1992, Proc. R. Soc. Edinburgh, 99B, 137
- Hershko, 1978, J. Lab. Clin. Med., 92, 144
- Pippard, 1978, Clin. Sci. Mol. Med., 54, 99
- Wolfe, 1990, Semin. Hematol., 27, 117
- Galanello, 2003, J. Clin. Pharmacol., 43, 565, 10.1177/0091270003253350 · doi:10.1177/0091270003253350 · Paper page
- Piga, 2003, J. Hematol., 88, 489
- Oakley, 1973, JAMA, J. Am. Med. Assoc., 225, 395, 10.1001/jama.1973.03220310031006 · doi:10.1001/jama.1973.03220310031006
- Albert, 1947, Br. J. Exp. Path., 28, 69
Cited by
Items 101–142 of 142
Rational Design of Copper and Iron Chelators to Treat Wilson's Disease and Hemochromatosis
Gateau, C., Mintz, E., & Delangle, P. (2014) · Wiley eBooks · doi:10.1002/9781118697191.ch11 · Cited by 10
Wada, A., Umeki, Y., Annoura, T., & Saito‐Nakano, Y. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00418 · Cited by 6
Harrington, J. M., Mysore, M. M., & Crumbliss, A. L. (2018) · Dalton Transactions · doi:10.1039/c8dt01329b · Cited by 6
Zhang, H., Shen, D., Zhang, Z., Kang, H., & Ma, Q. (2023) · Journal of Cultural Heritage · doi:10.1016/j.culher.2023.11.007 · Cited by 6
Mesquita, L., Mesquita, R. B. R., Leite, A., Moniz, T., Rangel, M., & Rangel, A. O. S. S. (2020) · Communications in Soil Science and Plant Analysis · doi:10.1080/00103624.2020.1751186 · Cited by 6
“The 3,4-HPO ligands are synthetically versatile bidentate oxygen ligands, that allow the synthesis of a variety of chelators of variable physicochemical properties, and provide a six oxygen coordination sphere for Fe (Burgess and Rangel 2008; Cusnir et al. 2017; Ferreira et al. 2018; González et al. 2017; Mesquita et…”
BackgroundShahid, M., Sharma, P. K., Siddiqi, Z. A., Sama, F., Ansari, I. A., & Khalid, M. (2014) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2014.01.072 · Cited by 6
Wang, Q., & Franz, K. J. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.11.004 · Cited by 6
Silva-Brea, D., Aduriz‐Arrizabalaga, J., Sancho, D. D., & López, X. (2024) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2024.112807 · Cited by 5
Moniz, T., Feio, M. J., Silva, D., de Castro, B., & Rangel, M. (2018) · Medicinal Chemistry Research · doi:10.1007/s00044-018-2165-1 · Cited by 6
“Ligands of the 3-hydroxy-4-pyridinone (3,4-HPO) class are well known for their biomedical applications (Liu and Hider 2002a, b; Zhou et al. 2011, 2012; Santos et al. 2012) and the antibacterial activity of this family of molecules against Gram (+) and Gram (−) bacteria has also been reported (Musk…”
Background5‐Hydroxypyran‐4‐one derivatives as potential therapeutic iron–chelating agents
Li, J., Abbate, V., Jurach, J., Zhang, G., Kong, X., & Hider, R. C. (2016) · ChemistrySelect · doi:10.1002/slct.201600022 · Cited by 5
Self-citationLewis, F. W., Bird, K., Navarro, J.-P., Fallah, R. E., Brandel, J., Hubscher‐Bruder, V., Tsatsanis, A., Duce, J. A., Tétard, D., Bourne, S., et al. (2022) · Dalton Transactions · doi:10.1039/d1dt02604f · Cited by 5
Queirós, C., Leite, A., Silva, A. M. G., Gameiro, P., de Castro, B., & Rangel, M. (2015) · Polyhedron · doi:10.1016/j.poly.2014.10.003 · Cited by 6
In vitro antiproliferative study of novel adamantyl pyridin-4-ones
Peroković, V. P., Car, Ž., Opačak‐Bernardi, T., Martin‐Kleiner, I., Kralj, M., & Tomić, S. (2017) · Molecular Diversity · doi:10.1007/s11030-017-9763-6 · Cited by 5
Iron-Binding and Anti-Fenton Properties of Novel Amino Acid-Derived Cyclic Imide Dioximes
Mravljak, J., & Jakopin, Ž. (2019) · Antioxidants · doi:10.3390/antiox8100473 · Cited by 4
“Its chelation is also beneficial in cases of thalassemia to neutralise the iron overload in the body [15].”
BackgroundRecent advances in therapeutical applications of the versatile hydroxypyridinone chelators
Sharma, S., Baral, M., & Kanungo, B. K. (2022) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1007/s10847-021-01114-1 · Cited by 4
“HOPOs belong to a class of ligands with O donor sites with very high binding efficiency with trivalent metal ions [24] and come out as outstanding metal chelators possessing crucial roles in the life processes, and therefore chelation therapy has been developed as a vital therapeutic approach for few diseases [25].”
BackgroundN-Based Polydentate Ligands and Corresponding Zn(II) Complexes: A Structural and Spectroscopic Study
Volpi, G., Zago, S., Rabezzana, R., Diana, E., Priola, E., Garino, C., & Gobetto, R. (2023) · Inorganics · doi:10.3390/inorganics11110435 · Cited by 4
“…derivatives captured escalating focus for their intriguing skeleton, and then for their use in supramolecular architectures [22–24], catalysis [25,26], high selectivity for ions and small-molecules recognition, supramolecular chemistry [27,28] and as chelating drugs for medical treatment [29–35].”
Holbein, B. E., Ang, M. T. C., Allan, D. S., Chen, W., & Lehmann, C. (2021) · Sustainable agriculture reviews · doi:10.1007/978-3-030-58259-3_8 · Cited by 6
Poli(Rutin) micro/nanogels for biomedical applications
Sahiner, M., & Sagbas, S. (2021) · Hittite Journal of Science & Engineering · doi:10.17350/hjse19030000228 · Cited by 3
Basic Principles of Metal Chelation and Chelator Design
Hider, R. C., & Ma, Y. (2016) · Royal Society of Chemistry eBooks · doi:10.1039/9781782623892-00024 · Cited by 3
Self-citationIntracellular Iron Binding and Antioxidant Activity of Phytochelators
Silva, F. T., & Espósito, B. P. (2021) · Biological Trace Element Research · doi:10.1007/s12011-021-02965-y · Cited by 7
“Due to their suitable binding moieties (catecholates, hydroxypirones, α-hydroxycarboxylates [5]), phytochelators are candidates for iron chelation in IOD [4].”
BackgroundTanabe, T., Hori, M., Kimura, N., Tadokoro, R., Nagaoka, K., & Funahashi, T. (2025) · BPB Reports · doi:10.1248/bpbreports.8.1_9 · Cited by 2
Antioxidant activity and functional properties of grey mullet (Mugil cephalus) protein hydrolysates
Kong, L.-M., Cui, S., Huo, Y., Zhu, Q. X., Wei, X., & Zhou, T. (2021) · International Food Research Journal · doi:10.47836/ifrj.28.4.19 · Cited by 2
“Ferrous ion-chelating activity In the presence of molecular oxygen, the redox cycle between the two most stable oxidation states of iron (Fe(II) and Fe(III)) generates ROS such as the toxic hydroxyl radical (Zhou et al., 2012).”
BackgroundSelf-citationChen, C., Chen, Y., Cao, Y., Ma, Y., & Hider, R. C. (2017) · Canadian Journal of Chemistry · doi:10.1139/cjc-2017-0545 · Cited by 2
Self-citationHolder, A. A. (2013) · Annual Reports Section A (Inorganic Chemistry) · doi:10.1039/c3ic90007j · Cited by 2
Reply to “The Dual Personality of Iron Chelators: Growth Inhibitors or Promoters?”
Zurawski, D. V., Jacobs, A. C., Thompson, M. G., & Palys, T. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00134-13 · Cited by 2
“With systemic applications, these concentrations are not possible because of toxicity concerns, but for wound infections, a topical, nonsystemic application could be considered and was also highlighted in a recent review (3).”
BackgroundInteractions Between Iron Metabolism and the Endocannabinoid System in Bacterial Infections
Dickson, K., Zhou, J., & Lehmann, C. (2025) · Antibiotics · doi:10.3390/antibiotics14060614 · Cited by 1
Chelators as Antineuroblastomas Agents
D’Acunto, C. W., Gbelcová, H., Kaplánek, R., Pospíšilová, M., Havlík, M., & Ruml, T. (2023) · Physiological Research · doi:10.33549/physiolres.935184 · Cited by 1
Lewis, F. W., & Tétard, D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804562-6.00020-8 · Cited by 2
Biological and Biomedical Aspects of Metal Phenolates
Ming, L. (2014) · Wiley eBooks · doi:10.1002/9780470682531.pat0602 · Cited by 3
Quelantes bifuncionais para o tratamento de neurodisfunções associadas ao ferro
de Carvalho, R. S. M. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2019.tde-02082019-081346 · Cited by 2
Klinik Olarak Faydalı Demir Bağlayıcı Ligandların Tasarım Özellikleri
Özbolat, G., & Tuli, A. (2017) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.303588
Nam, G., Yi, Y., Lee, H. J., Lee, J., Kang, J., & Lim, M. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.14902-9
Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile
Contel, M. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-316-0 · Cited by 1
Cotton, S. A. (2013) · Annual Reports Section A (Inorganic Chemistry) · doi:10.1039/c3ic90020g
Moniz, T., Silva, A. M. N., de Castro, B., & Rangel, M. (2024) · Boletim da Sociedade Portuguesa de Química · doi:10.52590/m3.p708.a30002746
Maia, M., Monteiro, A. R., Martins, M. S., Martínez-González, L., Martínez, A., Remião, F., Silva, R. V. D. S., & Sousa, E. (2026) · ChemMedChem · doi:10.1002/cmdc.70352
“Analyzing the chemical structure of the compounds tested, the results obtained are in accordance with the expected, considering that none of the compounds possesses important groups for Fe(III) accommodation, such as catecholate, hydroxamate, or hydroxya-cid [46, 47].”
BindingDB Entry 50017363: Pyridones in drug discovery: Recent advances.
BindingDB (2023) · UC San Diego · doi:10.7270/q2f47t69
BindingDB (2020) · UC San Diego · doi:10.7270/q2vx0kjw
BindingDB Entry 50008570: CN128: A New Orally Active Hydroxypyridinone Iron Chelator.
BindingDB (2021) · UC San Diego · doi:10.7270/q2dj5k17
BindingDB (2022) · UC San Diego · doi:10.7270/q28p646m
Metadata
- Authors
- Zhou, T., Ma, Y., Kong, X., & Hider, R. C.
- Affiliations
- Zhejiang Gongshang University (CN)
- King's College London (GB)
- Corresponding author
- Hider, Robert C.
- Venue
- Dalton Transactions
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2012
- Volume
- 41
- Issue
- 21
- Pages
- 6371
- ISSN
- 1477-9226 (ISSN-L)
- 1477-9234
- OpenAlex
- W2028066320
- Cited by
- 136
- References
- 142
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 6 · 2023: 5 · 2022: 10 · 2021: 13 · 2020: 12 · 2019: 10 · 2018: 14 · 2017: 13 · 2016: 7 · 2015: 12 · 2014: 11 · 2013: 15 · 2012: 5
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Dalton Transactions (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- iron chelators, chelation therapy, iron overload, beta-thalassaemia major, sickle cell disease, neurodegenerative diseases, microbial infection, drug design, iron toxicity
- MeSH terms
- Anti-Bacterial Agents, Humans, Iron Chelating Agents, Drug Design, Iron Overload
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.